tiprankstipranks
Blurbs

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Wrap Technologies (WRAP), Geron (GERN) and Capricor Therapeutics (CAPR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Wrap Technologies (WRAPResearch Report), Geron (GERNResearch Report) and Capricor Therapeutics (CAPRResearch Report).

Wrap Technologies (WRAP)

In a report released yesterday, Allen Klee from Maxim Group maintained a Hold rating on Wrap Technologies. The company’s shares closed last Thursday at $2.03, close to its 52-week low of $1.60.

According to TipRanks.com, Klee is ranked 0 out of 5 stars with an average return of -23.3% and a 21.5% success rate. Klee covers the Technology sector, focusing on stocks such as Research Solutions, Iveda Solutions, and CareCloud, Inc.

The word on The Street in general, suggests a Hold analyst consensus rating for Wrap Technologies with a $2.50 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Geron (GERN)

Needham analyst Gil Blum reiterated a Buy rating on Geron today and set a price target of $3.00. The company’s shares closed last Thursday at $2.05.

According to TipRanks.com, Blum is a 1-star analyst with an average return of -4.0% and a 45.1% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Rocket Pharmaceuticals, and Aeglea Biotherapeutics.

Currently, the analyst consensus on Geron is a Strong Buy with an average price target of $4.67, an 117.2% upside from current levels. In a report issued on July 28, B.Riley Financial also initiated coverage with a Buy rating on the stock with a $4.00 price target.

Capricor Therapeutics (CAPR)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics yesterday and set a price target of $12.00. The company’s shares closed last Thursday at $5.28.

According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -38.2% and a 14.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Brooklyn ImmunoTherapeutics, and SELLAS Life Sciences Group.

Currently, the analyst consensus on Capricor Therapeutics is a Moderate Buy with an average price target of $15.00, which is a 212.5% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on WRAP:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More